Zhejiang Jingxin Pharmaceutical Co Ltd
002020
Company Profile
Business description
Zhejiang Jingxin Pharmaceutical Co Ltd is an integrated pharmaceuticals enterprise that focuses on manufacturing, R&D, and marketing. It offers finished dosage forms which include tablets, capsules, and injections in the areas of antilipemic, antidiabetic, cholesterolemia, luoroquinolones, cephalosporin, gastrointestinal promotion, anti-inflammatory analgesic, and antibiotics; APIs, and Chinese herbal drugs. The products are sold to overseas markets such as South-east of Asia, South Asia, Latin America and Europe.
Contact
No.800 Xinchang East Road
Yulin subdistrict
Zhejiang Province
Xinchang312500
CHNT: +86 57586298518
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
3,869
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,273.84 | 35.67 | 0.43% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |